The Jackson Laboratory Cancer Center (JAXCC) is undergoing a profound expansion of its membership, driven by new cancer-focused leadership and the opening ofthe JAX Genomic Medicine campus. Combined with the revitalization of the program at JAX Mammalian Genetics (Bar Harbor), the JAX will more than triple the cancer-focused faculty. The recruitment of eight new members since January 2012, when Dr. Liu became the JAXCC Director demonstrates the feasibility of this plan. The new JAXCC members bring new cancer research and technological expertise and a strong translational research capability to the Cancer Center. Institutional commitment to these new investigators is estimated at $19 million over the next five years. Developmental funds are a crucial factor in assuring the JAXCC's continued growth and productivity. In the previous grant cycle, new investigator funds were used to support seven junior faculty members. Funds are requested for partial support of new investigators, which will be leveraged by significant institutional commitment of funds. The strategic plan calls for the recruitment of 8 additional JAXCC members over the next 5 years, with institutional commitment estimated at $22 million. The overall goals in recruiting to the Cancer Center, determined in consultation with internal and external advisory committees include: 1) expanding the focus on cancer systems biology and cancer genomics;2) engaging translational sciences that include cancer pharmacology/systems pharmacology, chemical biology, and molecular pathology to enrich the basic science focus;and 3) strategically recruiting faculty who will strengthen orthogonal approaches to cancer, such as experts in systems computational biology, and aging. The result will be a cancer focus that comprises research focused on human genetics and genomics in Connecticut, tightly integrated with mouse genomics expertise in Maine to model the complexity of the human cancer genome. The pilot project program is an essential part of the plan to achieve the JAXCC's strategic goals. Projects are awarded based on the quality ofthe science, their anticipated contribution to one or more strategic goals, and the plan for securing federal funding, especially from NCI, for the mature project. In the previous grant cycle, 12 proposals were funded, including 9 since 2012. CCSG ($156,556) and institutional ($367,645) funds supported the project. In total, the funded projects support collaborations among 9 JAXCC members and 8 external institutions. One publication has resulted and three are in preparation. Nine grant proposals based on those pilots have been submitted to peer-reviewed agencies to date;2 were awarded, and 3 are under review. An increase in funds is requested for expansion of the pilot project program, with at least a one to one match from institutional funds. Projects that develop translational technologies that will move basic science to clinical impact are of special priority. Oversight ofthe program has been strengthened. The Scientific Executive Committee (SEC) sets the priorities for the annual proposal solicitation, works with applicants to refine a research plan that achieves the strategic goal(s), approves awards, and provides scientific guidance for the project's duration. Dr. Tennent, Associate Director for Research Administration, monitors progress of each pilot toward stated milestones and tracks resulting grant and manuscript submissions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-29
Application #
8699300
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2019-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
29
Fiscal Year
2014
Total Cost
$92,563
Indirect Cost
$39,670
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Song, Delu; Grieco, Steve; Li, Yafeng et al. (2014) A murine RP1 missense mutation causes protein mislocalization and slowly progressive photoreceptor degeneration. Am J Pathol 184:2721-9
Chow, Kin-Hoe; Shin, Dong-Mi; Jenkins, Molly H et al. (2014) Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity. Cancer Res 74:4864-74
King Jr, Lloyd E; Silva, Kathleen A; Kennedy, Victoria E et al. (2014) Lack of response to laser comb in spontaneous and graft-induced alopecia areata in C3H/HeJ mice. J Invest Dermatol 134:264-6
Low, Benjamin E; Krebs, Mark P; Joung, J Keith et al. (2014) Correction of the Crb1rd8 allele and retinal phenotype in C57BL/6N mice via TALEN-mediated homology-directed repair. Invest Ophthalmol Vis Sci 55:387-95
Potter, Christopher S; Wang, Zhe; Silva, Kathleen A et al. (2014) Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS One 9:e85666
Hosur, Vishnu; Johnson, Kenneth R; Burzenski, Lisa M et al. (2014) Rhbdf2 mutations increase its protein stability and drive EGFR hyperactivation through enhanced secretion of amphiregulin. Proc Natl Acad Sci U S A 111:E2200-9
Roderick, Justine E; Tesell, Jessica; Shultz, Leonard D et al. (2014) c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123:1040-50
Korstanje, Ron; Caputo, Christina R; Doty, Rosalinda A et al. (2014) A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen ?3?4?5(IV) trimers. Kidney Int 85:1461-8
Grubb, Stephen C; Bult, Carol J; Bogue, Molly A (2014) Mouse phenome database. Nucleic Acids Res 42:D825-34
Inaki, Koichiro; Menghi, Francesca; Woo, Xing Yi et al. (2014) Systems consequences of amplicon formation in human breast cancer. Genome Res 24:1559-71

Showing the most recent 10 out of 736 publications